Stephen Beatty, president and CEO of Helix BioMedix, said: “This agreement is significant for Helix BioMedix as it addresses several critical components that are important to the company both now and in the future.
“First, our relationship with Peptisyntha is a major step towards ensuring that we can supply commercial quantities of peptides once products are developed through our pharmaceutical program. Second, this agreement will immediately provide peptide supplies to our marketing partners for our rapidly growing consumer product segment.”